Quality‐of‐Life Evaluation in an Interferon Therapy After Radical Surgery in Cutaneous Melanoma Patients

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Nursing

• Publication date

  2005-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00002820-200505000-00002PMID 15915059
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Psychological Stress and Antibody Response to Influenza Vaccination: When Is the Critical Period for Stress, and How Does It Get Inside the Body?

  2004cited by this paper
• [Incidence, pathoetiology and treatment of interferon-alpha induced neuro-psychiatric side effects].

  2003cited by this paper
• The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma

  2003cited by this paper
• Cognitive‐behavioral intervention for distress in patients with melanoma

  2003cited by this paper
• Cancer prevalence in Central Europe: the EUROPREVAL Study.

  2003cited by this paper
• Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.

  2001cited by this paper
• Patterns over time in quality of life, coping and psychological adjustment in late stage melanoma patients: An application of multilevel models

  2000cited by this paper
• Adjuvant therapy of melanoma with interferon‐alpha‐2b is associated with mania and bipolar syndromes

  2000cited by this paper
• Posttraumatic stress reactions after injury.

  2000cited by this paper
• A new American Joint Committee on Cancer staging system for cutaneous melanoma

  2000cited by this paper
• Cognitive Function and Quality of Life in Interferon Therapy for Melanoma

  2000cited by this paper
• Interferon‐α therapy for melanoma

  2000cited by this paper
• Mood and cognitive side effects of interferon-α therapy

  1998cited by this paper
• Mood and cognitive side effects of interferon-alpha therapy.

  1998cited by this paper
• Fatigue: definitions, mechanisms, and paradigms for study.

  1998cited by this paper
• Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha.

  1998cited by this paper
• The National Cancer Data Base report on cutaneous and noncutaneous melanoma

  1998influential reference
• Psychophysical Precedents of Migraine in Relation to the Time of Onset of the Headache: The Migraine Time Line

  1997influential reference
• Manic episodes in two patients treated with interferon alpha.

  1997cited by this paper
• Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.

  1996cited by this paper
• Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

  1996cited by this paper
• Interferons in melanoma.

  1996cited by this paper
• Psychological responses to malignant melanoma. An investigation of traumatic stress reactions to life-threatening illness.

  1995cited by this paper
• Fatigue in patients with cancer receiving interferon alpha.

  1995cited by this paper
• Differential long-term impact of in-hospital symptoms of psychological stress after non-Q-wave and Q-wave acute myocardial infarction.

  1992cited by this paper
• Psychological distress among oncology outpatients. Prevalence and severity as measured with the Brief Symptom Inventory.

  1987cited by this paper
• Psychosocial Distress in Oncology Outpatients

  1985cited by this paper
• Recognition of mental distress and diagnosis of mental disorder in primary care.

  1985cited by this paper
• Stressful Events, Dysphoric Mood, and Immune Responsiveness

  1984cited by this paper
• Moods that predict coming migraine headaches

  1984cited by this paper
• The National.

  1892cited by this paper

• Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer

  2019cites this paper
• S3‐Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms – Update 2015/2016, Kurzversion 2.0

  2017cites this paper
• Comparison of quality of life among long-term melanoma survivors and non-melanoma controls: a cross-sectional study

  2017cites this paper
• A Qualitative Study of Quality of Life Concerns following a Melanoma Diagnosis

  2017cites this paper
• Feasibility of Pegylated Interferon in Children and Young Adults With Resected High‐Risk Melanoma

  2016cites this paper
• Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma

  2014cites this paper
• Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

  2013cites this paper
• Malignes Melanom S3‐Leitlinie “Diagnostik, Therapie und Nachsorge des Melanoms”

  2013cites this paper
• S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version

  2013cites this paper
• ImmunoTargets and Therapy Immunotherapy in the management of melanoma : current status

  2013cites this paper
• Health-related quality of life in patients with melanoma: overview of instruments and outcomes.

  2012cites this paper
• Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b.

  2012cites this paper
• Understanding and managing interferon-&agr;-related fatigue in patients with melanoma

  2012cites this paper
• Health-related Quality of Life Before and During Adjuvant Interferon-&agr; Treatment for Patients With Malignant Melanoma (DeCOG-Trial)

  2011cites this paper
• Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: patients' and doctors' views.

  2011cites this paper
• Assessment of patient-reported outcomes in patients with melanoma.

  2011cites this paper
• Assessment of Patient Reported Outcomes (PROs) in Melanoma Patients

  2010cites this paper
• Living with hepatitis C and treatment: the personal experiences of patients.

  2009cites this paper
• A systematic review of health-related quality of life in cutaneous melanoma

  2009influential citation
• The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818A>G polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population

  2009cites this paper
• Psychiatrische Symptombelastung vor und während adjuvanter Therapie mit Interferon alpha 2a bei malignen Melanom Patienten

  2009cites this paper
• Health Management Program: High-Dose Interferon Alfa-2b in Malignant Melanoma

  2008cites this paper
• Lebensqualität bei Melanom- Patienten unter adjuvanter Interferon- alpha 2a-Therapie

  2008cites this paper
• Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma

  2008cites this paper
• Living with Hepatitis C and treatment : a phenomenological study of the experience of patients and their partners

  2007cites this paper
• Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial

  2006cites this paper